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1. Introduction
Acne vulgaris is an extremely prevalent skin condition,1
affecting the majority of teenagers to a certain degree at some
point. The impact on the quality of life of young people is highly
significant.2 It has a greater negative effect on the emotions and
social functioning of teenagers than diseases like asthma and
epilepsy.3 It is often associated with anxiety, depression and
unemployment.4 The impact of the condition is often difficult to
determine clinically,5 but one can assume that almost all acne
patients will experience this impact to some degree.
Medical treatment can make a very big difference,6 often
clearing the condition completely, or bringing about significant
improvement in those who do not experience complete
clearance.
The ‘Global Alliance to Improve Outcomes in Acne’ was
formed in 2001 as a world-wide effort to bring together a group
of recognised experts in the field of acne treatment. The aim was
to review the current state of knowledge in this field, to work
through all the relevant literature available systematically, to
have meetings to discuss the evidence thus collected, and to
draw up a set of recommendations for acne management to be
distributed to all participating countries where the general
implementation of these guidelines would be encouraged.
Two main groups were formed, in America and Europe.
Meetings were held separately but information was shared and
there was unification of the ultimate guidelines. Africa, Australia
and South America were included with the European group and
the South African delegates attended most of the meetings in
Europe.
Four meetings were held in Europe. Brussels hosted these in
November 2002 and January 2003, Seville in April 2003 and
Barcelona in October 2003.
The information and recommendations originating from these
meetings were published in the Journal of the American Academy
of Dermatology (2003; 49: S1-38) and were brought back to South
Africa and discussed with South African dermatologists in a
series of meetings held during March and April 2004 at six main
centres in the country. About 80% of local dermatologists
attended these meetings, commented on the recommendations,
and gave input on special circumstances applicable to South
Africa. All the information gathered from these meetings was
then incorporated into the guidelines as set out in the rest of this
document. The recommendations are therefore highly
representative of the current global approach to the treatment of
acne, and at the same time reflect the thinking of the majority of
local dermatologists. The guidelines should carry the necessary
weight and authority to ensure general acceptability among all
South African health care workers who manage acne cases and
should therefore be applied by dermatologists, general medical
practitioners, gynaecologists, pharmacists, nurses and also
beauticians.       
This review discusses use of the major classes of anti-acne
therapy and the way it should be used, with recommendations
in each instance, and management of the different grades of
acne vulgaris.
CLINICAL GUIDELINE
Objective. The guidelines on the management of acne vulgaris
have been developed in an attempt to improve the outcomes of
acne treatment in South Africa. This extremely common
condition has a major impact on the quality of life of South
African young people and it is expected that if implemented,
these guidelines will play a role in improving this situation.
Recommendations. All health care workers involved in the
management of acne should take note of these guidelines and
endeavour to implement them in clinical practice.  All
treatment methods and procedures not substantiated by
evidence from the literature should be discontinued and
avoided to decrease the financial burden of acne treatment.
Validation. These guidelines were developed through general
consensus by a group of about 40 internationally recognised
experts in the field of acne treatment (the Global Alliance to
Improve Outcomes in Acne, see details below) and further
refined for South African circumstances by the majority of
South African dermatologists who attended a series of six
discussions held in the major centres of South Africa during
2004.
Guideline sponsor. The meetings of the Global Alliance to
Improve Outcomes in Acne as well as the South African
discussion meetings were sponsored by Galderma.
S Afr Med J 2005; 95: 883-892.
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2. Why Guidelines?
Guidelines for the treatment of acne vulgaris are necessary
because a huge variation exists in the approach of different
dermatologists and other health care workers involved in acne
management. Some of the methods used are not supported by
any evidence in the literature and some methods are clearly
detrimental to the patient, the community or the patient’s
finances. A significant proportion of dermatologists also
deviate from the accepted regimens. In our present climate of
managed health care, health care funders are increasingly
relying on evidence-based decisions when deciding on
reimbursement of treatments. Similar trends are followed in the
public medicine sector.
One should also remember that non-dermatologists treat
more acne than dermatologists, hence it is particularly
important for the former to have a set of practical guidelines to
facilitate the best possible outcomes in acne treatment.
A further consideration is that new evidence is constantly
emerging and new drugs are being developed on a regular
basis. These factors should be taken into account when
guidelines are drawn up.  Guidelines can never be static, and
constant revision is the norm. Guidelines were published in
this Journal in 1999; while many of these principles are still
applicable, they have been largely revised here.
3. Pathophysiology of acne vulgaris
It is very important to be knowledgeable about the
pathophysiology of this condition. The pathogenetic factors
represent specific targets for treatment and it has been proved
that combinations of treatment directed at different
pathogenetic factors will achieve better results than different
treatment methods aimed at the same factors.7
The main pathogenetic factors involved in acne are the
following: (i) production of androgens in the body; (ii)
excessive sebum production; (iii) abnormal desquamation of
the follicular epithelium in the duct of the sebaceous gland; (iv)
proliferation of Propionibacterium acnes; and (v) inflammatory
and immunological responses.
It is important to realise that acne is androgen-dependent.
The main hormone responsible for increasing sebum
production is dihydrotestosterone, converted from testosterone
in the sebaceous glands by the enzyme 5-alpha-reductase.8-10
The primary lesion in acne is the microcomedo.  It is not
visible to the naked eye but histological analysis shows
hyperkeratosis of the intrafollicular sebaceous ducts and
dilatation of the sebaceous glands.  In the acne-prone patient,
about 30% of facial follicles will be in this state at any given
time. An additional concept is that of the inflammatory
microcomedo, still not visible to the naked eye, but which
shows inflammation on histological examination.11 This lesion
forms an important target in the treatment of acne, especially
as far as maintenance treatment is concerned.
It has also become evident that interleukin-1-alpha, an
inflammatory cytokine, plays a major role in inducing
inflammation in the microcomedo, with resultant activation of
the entire acne process.
P. acnes is a Gram-positive, pleomorphic, anaerobic rod; its
important role in acne has been well proven.12  There is a very
strong correlation between the number of these bacteria and
the level of sebum production16 and it has been shown that
only living propionibacteria are able to induce inflammation in
acne cysts.13-16 Humoral and cellular immune responses
induced by this bacterium, namely the generation of
extracellular enzymes,17 the production of interleukin-1-alpha,18
the generation of heat-shock proteins and a mitogenic effect on
T-cells, correlate with acne severity.  A positive chemotactic
effect on neutrophils is an important consequence of the
breakdown of sebum into free fatty acids by bacterial lipase.19,20
These bacteria are not involved in comedogenesis but they are
very prominent in inducing inflammation through
immunological mechanisms.21
At present there is no evidence to suggest that coagulase-
negative Staphylococcus aureus, S. epidermidis or Pityrosporum
ovale play any significant role in the pathogenesis of acne
vulgaris. 
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Consensus of the Global Alliance 
Acne has very significant impact on patients
• Negative effect on emotions and social functioning
• Associated with anxiety, depression, unemployment
• Impact not always easy to assess clinically
Recommendations of the Global
Alliance 
Quality of life
• Effective treatment dramatically improves a patient’s
quality of life (QOL)
• Use of a simple QOL assessment tool can help clinicians
optimise therapy
Consensus of the Global Alliance 
Knowledge of pathophysiology should influence
treatment
• Primary pathophysiological factors in acne:
• Androgen production
• Excessive sebum production
• Abnormal desquamation of the follicular epithelium
• P. acnes proliferation
• Inflammation and immune response
• Treatment should target as many factors as possible
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4. Clinical diagnosis of acne vulgaris
Acne vulgaris can present with a variety of skin lesions,
namely comedones, both open and closed, inflammatory
papules, pustules, nodules, cysts, conglobate lesions, sinuses,
scars and even ulcers.  However, several other skin diseases
present with very similar-looking skin lesions and a diagnosis
is not always as straightforward as it would seem. It is always
important to ascertain whether comedones are present because
comedones are virtually diagnostic of acne vulgaris and it is
very difficult to make this diagnosis in their absence.
While acne involves mostly the face it often extends onto the
trunk, most often the back, and can also involve the upper
arms, thighs and even the buttocks.  The scalp is very rarely
involved even though it is richly supplied with sebaceous
glands.
5. Grading of acne vulgaris
It is necessary to grade acne vulgaris according to severity; this
is very important in decision making when treatment is
planned.  Grading can, however, be very problematic and
highly subjective, especially when clinicians also use the
number of different skin lesions to determine severity.
The simplest way of grading acne is based on the
predominant type of lesion present on the skin, regardless of
number.  This makes therapeutic sense if one assumes that, for
example, one comedo present on the face will respond as well
to treatment as a thousand comedones.  The acne is therefore
graded according to the type of lesions present and the latter
will dictate the form of therapy implemented. Grading is
always done according to the most severe lesions present.
One can therefore grade acne as follows:
• Grade 1: Comedones only
• Grade 2: Inflammatory papules present in addition to the
comedones
• Grade 3: Pustules present in addition to any of the above
• Grade 4: Nodules, cysts, conglobate lesions or ulcers present
in addition to any of the above
More complicated grading systems rely heavily on the use of
photographs or diagrams. In such systems the clinical
appearance of the patient is compared with a standard set of
photographs and severity is decided on according to
correspondence with a particular photograph. This system is
often difficult to reproduce, highly subjective, and does not
always reflect the exact pathology present and therefore is not
reliable in indicating the exact treatment required for the
particular case.
In addition to the actual grade of the acne, one should take
into account the extent of involvement because this will
certainly influence the decision on the treatment method. The
presence of scarring should also be noted. A patient with
scarring would immediately be placed in a more severe
category than one without scarring. 
6. Use of antibiotics in treatment of
acne vulgaris
Antibiotics are the most frequently used type of drug in the
treatment of acne.  They can be used both topically and
systemically, the latter being far more effective.  It is generally
accepted that antibiotics, especially in topical form, are largely
abused in the management of acne and many of the problems
experienced with the use of antibiotics are due to the
inappropriate use of topical preparations.
It is not the purpose of this review to discuss the
pharmacology of these drugs in detail, but certain aspects of
the mechanisms of action and the most important side-effects
will be addressed.
Different classes of antibiotics are used in acne management.
Most frequently used are the tetracyclines, especially
doxycycline, lymecycline, minocycline and the older first-
generation tetracyclines. Erythromycin is also frequently used,
both topically and systemically, and the same applies to
clindamycin.  Co-trimoxazole is also commonly used,22,23 as it is
inexpensive and often highly effective.  As a rule the penicillins
are ineffective in this context.
6.1 Mechanism of action of oral antibiotics
The cyclines are the most widely studied group of drugs in this
regard. They exert both antibacterial and non-antibacterial
action in combating acne. Among the non-antibacterial
activities, inhibition of bacterial lipases, anti-inflammatory
activity and immunosuppression are among the most
important. For the cyclines as a group, 11 different anti-
inflammatory effects have been discovered, which include
among others, inhibition of neutrophil leucotaxis,24 reduction in
cytokine secretion, decrease in metalloproteinase activity and
direct inhibition of lymphocyte mitosis.25-28 These activities are
used in a variety of other diseases, but in acne the antibacterial
effects are probably the most important.
6.2 Propionibacterium resistance to antibiotics used
for acne
Successful treatment reduces the population of P. acnes but
does not eradicate it. Acne is not cured, there is merely a
temporary reduction in the number of bacteria.  Widespread
use of antibiotics has led to the emergence of resistance and
therapeutic failure.29,30 Therapeutic failure can also be caused
by poor compliance, incorrect use of the drug, inadequate
potency prescribed and folliculitis caused by other bacteria.
Antibiotic resistance among these bacteria has increased
dramatically over the past 25 years, with a figure of 62%
quoted for the UK at the moment.  Resistance is now an
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international problem, induced by the use of antibiotics.
Resistant bacteria can also be transferred to close contacts and
to and from physicians, with dermatologists being particularly
at risk. Several factors are at play in causing resistance. The
most important of these is the prescription of prolonged
courses of antibiotics, multiple courses of antibiotics and the
use of topical preparations. The edge of a topically treated area
will always have a zone where the concentration of antibiotic
will be suboptimal, encouraging the growth of resistant
bacteria.
6.3 How to prevent resistance
One should avoid the needless use of antibiotics; they are only
indicated for moderate to severe acne (grades 2 - 4). They
should be used in combination treatment and never as
monotherapy. Minimum duration of treatment should be 6
weeks and maximum duration 12 weeks. Strict compliance by
the patient is necessary, and if topical antibiotics are used they
should be combined with topical non-antibiotic antimicrobials
like benzoyl peroxide.
Antiresistance agents that can be used include benzoyl
peroxide, zinc acetate and oral isotretinoin.
6.4 Which oral cyclines are used in acne treatment?
Minocycline, doxycycline and lymecycline have similar
efficacy.31 As far as side-effects are concerned, doxycycline is
prone to cause phototoxicity and gastrointestinal disturbance
and minocycline can cause hyperpigmentation,
hypersensitivity syndromes, serum sickness-like illness and
drug-induced lupus.32,33 These side-effects are fortunately rare,
but nevertheless serious.34 It is recommended that if
minocycline is to be used for more than 3 months, liver
functions and ANA determination need to be done 3-monthly.35
Lymecycline appears to be free of these side-effects.36
Pharmacoeconomically, there is very little difference between
these 3 drugs, with doxycycline being slightly less expensive
than the other 2 in South Africa.
On the whole there is at the moment very little use for first-
generation tetracyclines like oxytetracycline in the treatment of
acne vulgaris. Their effectiveness cannot compare with that of
the more modern drugs and they are not significantly cheaper
any more, giving them poor cost-effectiveness ratios.
6.5 Optimal dosing of oral cyclines in acne
treatment
As mentioned above, the correct dosing is essential to prevent
bacterial resistance, and even though low doses have been
shown to be effective this will increase bacterial resistance. It is
therefore encouraged that high doses be used for the full
duration of treatment to increase efficiency and to reduce the
emergence of resistance.  
6.6 Optimal duration of oral antibiotic treatment
It has been shown that oral antibiotics will induce
improvement during the first 3 or 4 months of treatment, with
little improvement thereafter, while antibiotic resistance will
become more apparent after 4 months of treatment.  It is
therefore felt that courses of antibiotics for acne should be
limited to a maximum of 4 months.
Recommendations of the Global
Alliance 
Oral antibiotics for acne
• Oral cyclines should be considered as a first choice when
treating acne
• Lymecycline should be considered as a first-choice
antibiotic when treating moderate to severe inflammatory
acne
• Doxycycline or minocycline can be prescribed as second
choice
• First-generation tetracyclines should be considered a third
choice
• Erythromycin can be used in children under 12 years old or
during pregnancy
• Co-trimoxazole can be considered in selected cases
Recommendations of the Global
Alliance 
Optimal dosage for antibiotics in acne
• 300 - 600 mg per day for lymecycline
• 100 - 200 mg per day for doxycycline and minocycline
• One gram per day for oxytetracycline
• Topical antibiotics should never be used as monotherapy
Recommendations of the Global
Alliance 
Duration of antibiotic treatment
• Oral antibiotics should be prescribed for 3 months
• An additional month can be considered if a steady
improvement has been seen over the previous 3 months,
but total clearance has not been achieved
• Compliance should be checked in patients who do not
respond well
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7. Use of topical retinoids in acne
treatment
Topical retinoids target the microcomedo, which forms the
earliest precursor of visible acne lesions. These preparations
also have very significant anti-inflammatory effects through
inhibition of toll-like receptors, which is not only useful in
treating inflammatory acne, but also plays a major role in
treating the inflammatory microcomedo, as mentioned in the
discussion on the pathophysiology. They can therefore be used
with great success in established inflammatory acne, right from
the start of treatment,37 and they are also extremely useful in
maintenance therapy where long-term use can prevent the
formation of new lesions and suppress the further
development of inflammatory microcomedones.
The different topical retinoids available, namely tretinoin,
adapalene, isotretinoin and tazarotene, have similar efficacy38
but share a common side-effect in the form of initial irritation
on application.39 Of the four preparations, adapalene seems to
be the one least prone to cause significant irritation.40 This
irritation effect is more pronounced on the Highveld of South
Africa with its drier climate than on the coast.  It is therefore
important to use the cream formulations on the Highveld,
while the gel formulations can be freely used at the coast.
It is also very important to realise that topical retinoids
should be applied to the whole affected area and not only on
visible lesions.  This is because in addition to their therapeutic
effect on visible lesions, their main action is preventive,
working on skin without apparent lesions.
8. Use of topical benzoyl peroxide in
acne treatment
Benzoyl peroxide is an extremely useful preparation in the
management of acne.  It has a mild but significant keratolytic
effect, therefore acting in a comedolytic fashion, but is also a
broad-spectrum antimicrobial, acting in a non-antibiotic
fashion. It can therefore be used alone in cases of mild acne,41 in
combination with topical retinoids in severe comedonal and
early inflammatory acne, and as an antiresistance agent in
combination with systemic antibiotics when prolonged or
repeated courses of the latter are necessary.
Benzoyl peroxide is available in different strengths, usually
5% or 10% gels and creams, and in the form of facial washes.
9. Combination therapy for acne
vulgaris
Oral antibiotics and topical retinoids have been shown to have
synergistic mechanisms through independent processes.
Clearing of both inflammatory lesions and comedones is
faster42 and more complete with a combination of these 2
preparations than with antibiotics alone.43,44 The simultaneous
use of topical retinoids limits the duration of antimicrobial
therapy, enhances the penetration of antibiotics into the skin
and increases the follicular cell turnover allowing more
antibiotics to be transported into the sebaceous unit.41
Benzoyl peroxide can be added to topical retinoids and
systemic antibiotics in order to decrease resistance44 or it can be
used in combination with topical retinoids either on alternate
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Consensus of the Global Alliance 
Topical retinoids have multiple anti-acne actions
• Inhibits/reduces number of microcomedones
• Reduces mature comedones
• Reduces inflammatory lesions
• Promotes normal desquamation of follicular epithelium
• Anti-inflammatory
• Enhances penetration of other drugs
• Maintains remission by inhibiting microcomedones
Recommendations of the Global
Alliance
Topical retinoids in acne treatment
• Should be the primary form of treatment for most forms of
acne vulgaris
• Use early for best results
• Add antimicrobial therapy for inflammatory lesions when
present
• Should be applied to the entire affected area
• Essential part of maintenance therapy
Consensus of the Global Alliance 
Benzoyl peroxide is a useful adjunctive treatment
• Potent antimicrobial effects
• Slower-acting than systemic antibiotics
• No resistance reported to date
• Useful in patients with mild to moderate acne
Recommendations of the Global
Alliance 
Benzoyl peroxide 
• Use in patients with mild to moderate acne
• Apply once or twice daily to entire affected area
• Use lower strengths in persons with:
• Sensitive skin
• Very young or anxious patients
• Higher concentrations and washes for:
• Chest, shoulders, back
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days or on a daily basis, one being applied in the morning and
the other at night.
10. Importance of maintenance therapy
in acne
With the exception of a full course of systemic isotretinoin,
other acne therapies will merely suppress the process and not
cure the condition. This is especially applicable when systemic
antibiotics are used. It is therefore imperative that maintenance
therapy be instituted in all instances.45 Topical retinoids are the
treatment of choice for maintenance, as explained above, for a
minimum period of 12 months after completion of the initial
systemic treatment.  Benzoyl peroxide can be added to the
retinoids at this stage, especially if inflammatory lesions still
appear. Topical retinoids can also be used as maintenance
treatment after completion of a course of systemic isotretinoin
to prevent relapse.
Other preparations that can be used for long-term
maintenance are azelaic acid46 and salicylic acid, but these
represent the second and third choices. In females the use of
oral contraception, even without anti-androgen effect, also
represents excellent maintenance therapy, with or without
added topical retinoids.
11. Hormonal treatment of acne
vulgaris
Acne is an androgen-dependent condition and in females the
androgens can be effectively blocked or reduced, often leading
to significant improvement in or clearing of the condition.  It
represents an excellent choice for women who need oral
contraception and should be used early for patients with
moderate to severe acne who also have signs of androgen over-
Consensus of the Global Alliance 
Combination therapy is now standard of care for
mild to moderate acne
• Antimicrobial therapy plus topical retinoids is significantly
better than antimicrobials alone
• Clearance of both inflammatory lesions and comedones is
faster
• Combination therapy allows targeting of different
pathophysiological factors
• Topical retinoids are likely to enhance penetration of
antimicrobials, and to speed up action of antibiotics
• Topical retinoids added early, at start of treatment, give
fastest results
• Antibiotic can be discontinued when inflammatory lesions
resolve (3 - 4 months)
• If this is not possible, benzoyl peroxide or benzoyl
peroxide/antibiotic combination can be used
• Success can be maintained with topical retinoids
Recommendations of the Global
Alliance 
Combination therapy
• Oral antibiotics should not be used alone
• Oral antibiotics should not be combined with topical
antibiotics (increases the risk of bacterial resistance and
provides no additive action)
• Oral antibiotics should always be combined with a topical
retinoid from the start (3 pathogenic factors addressed)
• Benzoyl peroxide can be added to topical retinoids and
oral antibiotics in order to lower the incidence of bacterial
resistance
• Benzoyl peroxide should be added when longer courses of
antibiotics are used
• Topical retinoids and benzoyl peroxide can be used in
combination, either on alternate days or one in the
morning and the other at night
Consensus of the Global Alliance 
Maintenance therapy
• The microcomedo is the precursor of all acne lesions
• The process of microcomedo formation is permanent and
persists after acne is cleared
• Avoiding microcomedo formation has a preventive effect in
acne
• Microcomedones are the main target of topical retinoids
Recommendations of the Global
Alliance
Maintenance therapy
• After the acute phase of acne treatment (> 90%
improvement), maintenance therapy should always be
considered to limit relapse
• Topical retinoids are the treatment of choice for
maintenance therapy
• Suggested duration of maintenance therapy is 6 - 12
months
• Benzoyl peroxide can be added to topical retinoids to
lower bacterial resistance after antibiotic treatment
• Second choices for maintenance therapy are azelaic acid
and salicylic acid
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activity (Seborrhoea, Acne, Hirsutism, Androgenic alopecia
(SAHA)). It is useful in combination treatment, in women with
late-onset acne and in patients with prominent premenstrual
acne flares.
Ordinary combination oral contraceptives are often effective
in mild forms of acne,47 but for more severe forms antiandro-
gens must be used. The most effective available is cyproterone
acetate, either in a dosage of 2 mg added to ethinylestradiol, or
in a dosage of 10 mg taken for 15 days per cycle, added to a
contraceptive48 for more severe cases.  It is very important to
remember that cyproterone represents an effective progestogen,
therefore acting as effective contraception in combination with
ethinylestradiol and additional contraception is not necessary
when this preparation is prescribed.
Some authorities feel that the routine use of a topical retinoid
in combination with hormonal therapy brings about a much
quicker response than hormonal treatment alone and should be
regarded as an acceptable treatment option.
12. Systemic isotretinoin as treatment
for acne vulgaris
Very few authorities question the fact that this preparation
represents by far the most effective anti-acne treatment.52,53
Used in the correct dose, it very seldom fails to clear acne
completely and it effects a permanent cure in a high percentage
of cases, with cure rates varying from 38% to 66%, depending
on the definition of a cure.54
Isotretinoin addresses all the pathophysiological factors
involved in acne and usually achieves dramatic results even in
more severe cases.  There is no doubt that it is the drug of
choice for severe acne, with benefits far outweighing the risks
involved. It has, however, become fashionable to use the drug
for less severe cases where other more conservative treatments
may have been successful, often prescribed under pressure
from patients.  Physicians should nevertheless adhere to the
prescribed indications for use of this drug to prevent
medicolegal consequences.
This drug causes numerous side-effects, some of which are
serious, but most of which are not. Most patients experience
the period on this drug as very unpleasant, but they endure the
nuisance side-effects because they see the benefits very soon
after starting treatment.  The most serious side-effect is of
course the teratogenic effect of the medication.  This side-effect
is entirely preventable55 if the patient adheres to strict
contraception for a month before the start of treatment,
undergoes a negative pregnancy test thereafter and starts
medication on the third day of her next menstrual period.
Effective contraception has to continue for 1 month after taking
the last tablet in the course. Monthly negative pregnancy tests
are recommended in South Africa but are compulsory in the
USA. The patient should be fully aware of the risks, and
should sign written consent for use of the drug and indicating
her understanding that a therapeutic abortion would be
compulsory should she fall pregnant during treatment.
Consensus has not been reached on the issue of depression
and suicide resulting from the use of isotretinoin. Statistically
speaking, there is a lower incidence of suicide in patients who
are on treatment with this drug, compared with a similar
population not exposed to it. General consensus has not been
reached on whether a small subset of patients will react with a
depressive response in an idiosyncratic, unpredictable way.
Caution is advised in patients with a history of depression;
mood swings should be reported by the patient and the drug
should be discontinued should any symptoms of depression
occur on treatment.56-58
The other side-effects of isotretinoin are of a less serious
nature59 but the patient should be aware of the dry skin and
mucosae that will be experienced, the initial temporary
worsening of the acne, the photosensitivity that occurs in 5% of
cases, the possibility of joint and muscle pain, the severe night
blindness that can hamper driving at night, the possibility of
mild hair loss that may occur and the fact that liver enzymes
and triglyceride levels may become raised during treatment.
Blood tests to determine baseline liver enzyme levels and
triglycerides need to be done before treatment starts and
should be repeated after 1 month of treatment. Should the 
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Consensus of the Global Alliance 
Hormonal therapy is useful in androgen-driven
acne
• Excellent choice for women who need oral contraception
for gynaecological reasons
• Should be used early for patients with moderate or severe
acne or with SAHA signs
• Useful in combination treatment
• Useful in women with late-onset acne
Recommendations of the Global
Alliance 
Hormonal therapy
• Use early in female patients with clinical signs of
hyperandrogenism (endocrine evaluation –
dehydroepiandrosterone (DHEAS), testosterone, luteinising
hormone/follicle-stimulating hormone (LH/FSH) ratio)49,50
• Consider in women with normal serum androgens:
• Persistent inflammatory papules, nodules on lower face
• Prominent acne flare at menstruation
• Mainstay of hormonal therapy: oral contraceptives,
cyproterone acetate, drospirenone, spironolactone51
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baseline and 1-month values both be normal, further blood
testing is unnecessary.
The effect of isotretinoin on bone metabolism has been under
discussion for decades.60,61 Treatment with high dosages over
prolonged periods for diseases of cornification has been
associated with skeletal abnormalities including hyperostosis,
calcification of spinal ligaments and osteoporosis. It has
recently been shown that the normal 4 - 5-month course of
isotretinoin does not cause any skeletal abnormalities, but there
are no data available on patients who were exposed to long-
term, low-dosage use of this drug. This uncertainty, together
with the teratogenic effect, are the main reasons why long-term
low-dosage treatment should be strongly discouraged at this
stage.
At each visit the patient should be questioned about
headaches; nightly or early-morning headaches could indicate
raised intracranial pressure which is an uncommon side-effect
of this drug but which can be precipitated by the concomitant
use of tetracyclines or systemic corticosteroids. These last 2
drugs should be used with circumspection in these patients.
The correct indications for isotretinoin in acne are indicated
in the ‘Recommendations of the Global Alliance’ on this page. 
The dosage used for a full course of treatment is very
important.62-64 This should not be below 0.5 mg/kg per day and
should not exceed 1 mg/kg per day, in order to limit side-
effects. The duration of treatment is determined by the body
weight of the patient and the daily dose taken. One should aim
for a minimum target of 120 mg per kg as a total cumulative
dose but this can be increased to 150 mg per kg if a satisfactory
result has not been achieved once 120 mg/kg has been reached.
The chances for a permanent cure are dramatically reduced if
treatment is discontinued before the threshold of 120 mg/kg
has been reached, even if the acne has cleared completely
before then.
There may be an indication for the so-called pulse-dosage
regimen, where 0.5  mg/kg is taken daily on the first 7 days of
each month. This is usually free from side-effects, except for
the teratogenic effect, and has proved to be highly effective for
patients who relapsed after a previous full course of this drug,
as well as for older patients with chronic, indolent, resistant
acne.  South African dermatologists felt that this regimen
should be included in the accepted guidelines for this country.
A special set of circumstances in which low-dosage
continuous isotretinoin may be used, involves young teenagers
with very severe comedonal acne. These patients respond very
poorly to topical comedolytic agents initially, and a 4 - 6-month
course of 10 - 20 mg of isotretinoin per day can lead to prompt
clearance of these lesions, whereafter maintenance with topical
retinoids should be highly effective.
High-dosage vitamin A used to be a popular treatment for
acne in the past, but evidence for its effectiveness is lacking
and because of the severe potential toxicity of this medication,
its use in acne should be discouraged.
13. Other drugs that may be used in
acne treatment 
Many patients, especially among the poor, may not have access
to expensive modern treatments for very severe inflammatory
acne. In these cases a combination of co-trimoxazole and low-
dosage prednisone for a few weeks may give excellent results.
Another useful drug in this scenario is dapsone, which at a
dosage of 50 - 150 mg per day can bring about complete
clearance of nodular inflammatory acne.  The condition can be
controlled with long-term maintenance treatment, with low-
dosage dapsone being relatively safe, provided that the patient
has a normal glucose-6-phosphate dehydrogenase (G6PD) level
and that full blood counts are initially done regularly to detect
any resulting anaemia. 
Consensus of the Global Alliance 
Oral isotretinoin is standard of care for severe
acne 
• Targets all the pathophysiological factors
• May achieve dramatic results even in severe disease
• May be used more frequently in moderate and
unresponsive disease
• Side-effects common but manageable
• Variable rate of recurrence; retreatment may be needed




• Severe nodulocystic acne and its variants
• Inflammatory acne with scarring
• Moderate to severe acne unresponsive to treatment with:
• Three months of combination treatment including
systemic cyclines
• Four cycles of anti-androgen containing hormonal
treatment
• Acne with severe psychological distress
(dysmorphophobic patients) 
• Gram-negative folliculitis
• Frequently relapsing acne where repeated or prolonged
courses of systemic antibiotics are needed
• Patient counselling is critical (side-effects, teratogenicity,
monitoring)
• Typical dosage: 0.5 - 1 mg/kg/day, cumulative dosage 
120 - 150 mg/kg
• Pulse-dosing permitted for relapse cases or older patients
with chronic, indolent acne
• Recurrence is common; a topical retinoid should be used as
maintenance treatment after isotretinoin treatment
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14. Adjunctive therapies
The most important aspect of adjunctive therapy is the
patient’s understanding of the treatment.  This will reduce
lapses in compliance, improve outcomes and prevent problems
like drug resistance.
Skin care regimens are generally of very little use and never
cost-effective. The face should be cleansed twice daily with
water and soft soap and the use of moisturising creams should
be limited, except in patients taking systemic isotretinoin.
Office procedures such as comedo extraction, chemical peels
and intralesional corticosteroids may be useful in selected cases
but cannot replace medical treatment.
15. Management of the different grades
of acne vulgaris
Grade 1. This degree of acne should be managed topically. A
topical retinoid will suffice in most cases, but the addition of
benzoyl peroxide or azelaic acid may be necessary in resistant
cases.
Grade 2. In milder cases with superficial inflammatory
papules, one can follow the same treatment as above. However,
where the papules are more deeply situated, a systemic
antibiotic is indicated.
Grade 3. In these cases there is always a severe, deep
inflammatory process present with a marked influx of
neutrophils, necessitating systemic antibiotics. These should
always be used in combination with a topical retinoid and, if
the systemic treatment needs to go on for longer than 3
months, a topical antiresistance agent should be added.
Hormonal treatment can be used with good success at this
stage in female patients who desire contraception or who have
other gynaecological indications for this treatment.
Grade 4. Systemic isotretinoin represents the drug of choice
in these patients.  In females, an oral contraceptive combined
with anti-androgens can sometimes be effective. Systemic
antibiotics can bring about excellent improvement in these
cases, but the improvement is of short duration and these
drugs do not represent a long-term solution for this type of
acne; unacceptably long courses of antibiotics are usually
necessary.
16. Summary of Guideline principles
• Most acne cases should receive a retinoid, either systemically
or topically.
• Inflammatory acne responds very well to retinoids, and there
is consequently no need to delay their introduction into the
treatment regimen.
• The anti-inflammatory effect of retinoids starts in the
invisible microcomedo.
• Retinoids should be used in combination treatment from the
inception and as maintenance.
• The main purpose of the retinoids is to minimise the use of
antibiotics.
• Lymecycline appears to be the tetracycline of choice for acne
at the moment, based on its cost-effectiveness and side-effect
profile.
• Bacterial resistance involving P. acnes and other organisms is
a problem; if antibiotics are needed for more than 4 months,
one should always add benzoyl peroxide or another
antiresistance agent.
• Systemic retinoids represent the treatment of choice for
severe forms of acne.
• Systemic retinoids should not be given routinely for acne,
even in men.
• The use of topical retinoid maintenance after systemic
isotretinoin depends on the response to the systemic drug.
• Hormonal treatment can be used early and as monotherapy
in females who desire contraception and as maintenance.
17. References
1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults.
BMJ 1979; 1: 1109-1110. 
2. Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological
outpatients: an issue to  be recognized. Br J Dermatol 2000; 143: 983-991.
3. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life
in acne: a comparison with general medical conditions using generic questionnaires. Br J
Dermatol 1999; 140: 672-676. 
4. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386. 
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure
for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. 
891
November 2005, Vol. 95, No. 11  SAMJ
Consensus of the Global Alliance 
General acne management strategies form useful
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• Office procedures: comedo extraction, chemical peels, and
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